Introduction: Additional oral antidiabetic agents to metformin, sulfonylureas (SU) and
thiazolidinediones (TZD) are approved for the treatment of type 2 diabetes. Areas covered …

Objective: To review the oral and injectable pharmacologic treatment options for type 2
diabetes. Data Sources: A literature search was conducted using PubMed electronic …

Diabetes mellitus is considered one of the main threats to human health in the 21st century.
Diabetes is a metabolic disorder or a chronic condition where the sugar levels in blood are …

Despite enormous global efforts within clinical research and medical practice to reduce
cardiovascular disease (s)(CVD), it still remains the leading cause of death worldwide. While …

Dopamine action appears to play a role in changes that are seen in obesity, metabolic
syndrome and type 2 diabetes mellitus. Bromocriptine-QR (Quick Release), a dopamine …

The pharmacological management of diabetes in older people is complex and challenging.
It requires a comprehensive understanding of the individual beyond the diabetes itself …

Aim To assess the metabolic effects of dopamine agonists compared with placebo in
randomized controlled trials (RCTs) including adults with type 2 diabetes. Materials and …

Abstract Purpose of Review There are currently over 40 different drugs in 12 distinct classes
approved in the USA to treat patients with type 2 diabetes mellitus. This review summarizes …

An extended series of studies indicate that endogenous phase shifts in circadian neuronal
input signaling to the biological clock system centered within the hypothalamic …

Objectives: Type 2 diabetes mellitus (T2DM) is associated with a substantially increased risk
of cardiovascular disease (CVD). Bromocriptine-QR (B-QR), a quick release sympatholytic …